Management Team

Ora's senior management team possesses an average tenure of over 12 years. This unmatched level of experience ensures both protocol adherence and on-time development milestones.

The Ora Management Team is comprised of senior scientists and management executives who possess decades of highly specialized experience in ophthalmic product development. No other team in the world has accrued such deep knowledge across the full array of ophthalmic therapeutic areas, and across the full range of development stages from CMC through Phase IV studies. It is because of this deep ophthalmic experience that Ora is able to deliver accelerate timelines through superior study design and unparalleled protocol adherence. At the same time, we are able to avoid the development pitfalls that are so often encountered by CROs who, unlike Ora, do not specialize in the ophthalmic arena every moment of the day.

Stuart B. Abelson, MBA

President and CEO

Trusted leader with 20 years of general management experience including 10 years as President and CEO of Ora. Stuart has broad experience in business and marketing strategy, international operations, M&A, licensing, product innovation and R&D management, and business model innovation. He also serves on multiple non-profit and corporate boards.

David Hollander, MD, MBA

Chief Medical Officer

Board certified ophthalmologist with significant expertise in regulatory, trial design and endpoint selection; David leads the Ora Institute, the internal R&D group focused on method and model development.

David Hollander, MD, MBA

Donna Welch, RN, BSN

Chief Operating Officer

Senior Vice President Founding member of Ora, 25+ years of experience leading and executing ophthalmic clinical trials

George Ousler

Vice President, Dry Eye

Internationally recognized expert in dry eye drug development; 15 years of clinical research and development, study design, and regulatory in dry eye

Aron Shapiro

Vice President, Anti-Infective, Anti-Inflammatory, Retina, Glaucoma

12+ years of executing ophthalmic preclinical, clinical, regulatory strategy and full clinical execution of programs across a number of therapeutic areas, including glaucoma, retina, and inflammation

Paul Gomes, MS

Vice President, Allergy, Allergic Rhinitis

Expert in regulatory and trial design for ocular allergy; personally involved in the approval and marketing of 10 lead ocular allergy products, including the leading ocular allergy franchise Patanol /Pataday and most recent Lastacaft approval

Mark B. Abelson, MD, CM, FRCSC

Founder, Scientific Advisor

Harvard-trained, world-renowned scientist and cornea specialist.